Inquiry

CellFace™ Cell-Antibody (Anti-HLA DR beta) Conjugation (CAT#: CF-0922-ZP291)

DataSheet

Product Overview
Description	Employing live cells as therapeutics is a direction of future drug discovery. An easy and robust method to modify the surfaces of cells directly to incorporate novel functionalities is highly desirable. However, genetic methods for cell-surface engineering are laborious and limited by low efficiency for primary cell modification. Creative Biolabs has developed a single-step chemoenzymatic CellFace™ technology platform to transfer bio-macromolecules, such as an IgG antibody (MW∼ 150 KD), to the glycocalyx on the surfaces of live cells. Requiring no genetic modification, our CellFace™ allows for any antibody to be conjugated to the stimulatory surface receptors of immune cells to yield the additive effect of superior tumor targeting to its already potent and off-the-shelf biologic drug payloads. We applied CellFace™ to construct the CellFace™ cell-antibody conjugation (CAC). CellFace™ CAC can be prepared from multiple immune cells and stem cells, such as T cells, NK cells, macrophages, and mesenchymal stem cells. The modified CAC is expected to overcome the challenges that have prevented cell therapies from effectively targeting solid tumors.
Available Formats	CellFace™ T Cell-Antibody (Anti-HLA DR beta) Conjugation CellFace™ NK Cell-Antibody (Anti-HLA DR beta) Conjugation CellFace™ MA Cell-Antibody (Anti-HLA DR beta) Conjugation CellFace™ MSC Cell-Antibody (Anti-HLA DR beta) Conjugation CellFace™ HSC Cell-Antibody (Anti-HLA DR beta) Conjugation
Engineered Molecules	Antibody
Cell Type	T Cell; NK Cell; Macrophage; HSC; MSC; TIL; CIK; γδ T Cell; Treg; Dendritic Cell; Fibroblast; Chondrocyte; iPSC; B Cell
Application Notes	The CAC can be customized with both cell lines and primary cells according to customer needs. Please contact us for specific cells you needs.

Target
Target	HLA DR beta
Official Name	HLA-DRB1
Full Name	Major Histocompatibility Complex, Class II, DR Beta 1
Synonyms	Apolizumab;267227-08-7;1D10;HU1D10;K8-355;HLA-DRB1;major histocompatibility complex; class II; DR beta 1;HLA DR1B;DW2.2/DR2.2;MHC class II antigen;lymphocyte antigen DRB1;MHC class II HLA-DRw10-beta;human leucocyte antigen DRB1;MHC class II HLA-DR beta 1

Quality Control
Research Use Only	For research use only, not for diagnostic or therapeutic use.

Related products

CellFace™ NK Cell-Antibody CF823 (Anti-HLA DR beta) Conjugate (CAT#: CF-AB-P823)

All services are only provided for research purposes and Not for clinical use.

ONLINE INQUIRY

USA

United Kingdom

Germany